March 2023
1. RAI P, Okhomina VI, Kang G, Martinez HR, et al
   Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia.
   Am J Hematol. 2023 Mar 8. doi: 10.1002/ajh.26911.
   

   >> Share

   
   
2. LANSER L, Plaikner M, Schroll A, Burkert FR, et al
   Tissue iron distribution in patients with anemia of inflammation: results of a pilot study.
   Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26909.
   

   >> Share

   
   
3. COHEN AR
   Thalassemia enters a new age ... And more lies ahead.
   Am J Hematol. 2023;98:379-380.
   

   >> Share

   
   
4. AL-SAMKARI H, Grace RF, Glenthoj A, Andres O, et al
   Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency.
   Am J Hematol. 2023;98:E57-E60.
   

   >> Share

   
   
5. ADESINA OO, Brunson A, Fisch SC, Yu B, et al
   Pregnancy outcomes in women with sickle cell disease in California.
   Am J Hematol. 2023;98:440-448.
   

   >> Share

   
   
6. FORNI GL, Gianesin B, Musallam KM, Longo F, et al
   Overall and complication-free survival in a large cohort of patients with beta-thalassemia major followed over 50 years.
   Am J Hematol. 2023;98:381-387.
   

   >> Share

   
   
7. RECCHIUTI A, Federti E, Matte A, Mazzi F, et al
   Impaired pro-resolving mechanisms promote abnormal NETosis, fueling autoimmunity in sickle cell disease.
   Am J Hematol. 2023;98:E45-E48.
   

   >> Share

   
   February 2023
8. ALHOMOUD M, Soave R, Kluk MJ, Shore T, et al
   Acute Hemolytic Anemia After Hematopoietic Stem Cell Transplantation: An Unusual Invader.
   Am J Hematol. 2023 Feb 6. doi: 10.1002/ajh.26873.
   

   >> Share

   
   
9. BAIN BJ, Myburgh J, Lund K, Chaidos A, et al
   G6PD deficiency in patients identified as female.
   Am J Hematol. 2023;98:359-360.
   

   >> Share

   
   January 2023
10. GLASPY J, Gabrail NY, Locantore-Ford P, Lee T, et al
    Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies.
    Am J Hematol. 2023 Jan 29. doi: 10.1002/ajh.26865.
    

    >> Share

    
    
11. KANG HA, Barner JC, Lawson KA, Rascati K, et al
    Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
    Am J Hematol. 2023;98:90-101.
    

    >> Share

    
    
12. KANTER J, Thompson AA, Pierciey FJ Jr, Hsieh M, et al
    Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
    Am J Hematol. 2023;98:11-22.
    

    >> Share

    
    December 2022
13. ZHANG Y, Zhou H, Jiang Z, Wu D, et al
    Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial.
    Am J Hematol. 2022;97:1510-1519.
    

    >> Share

    
    November 2022
14. SEBASTIANI P, Steinberg MH
    Fetal Hemoglobin per Erythrocyte (HbF/F-cell) After Gene Therapy for Sickle Cell Anemia.
    Am J Hematol. 2022 Nov 24. doi: 10.1002/ajh.26791.
    

    >> Share

    
    
15. POTHAST CR, van Dijk K, Pool ES, Halkes CJM, et al
    SARS-CoV-2 mRNA vaccination of aplastic anemia patients is safe and effective.
    Am J Hematol. 2022 Nov 13. doi: 10.1002/ajh.26780.
    

    >> Share

    
    
16. GANGAT N, Begna KH, Al-Kali A, Hogan W, et al
    Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.
    Am J Hematol. 2022 Nov 8. doi: 10.1002/ajh.26778.
    

    >> Share

    
    
17. ACHEBE MO, Mandell E, Jolley K, Park HS, et al
    Pagophagia and Restless Legs Syndrome are Highly Associated with Iron Deficiency and Should Be Included in Histories Evaluating Anemia.
    Am J Hematol. 2022 Nov 2. doi: 10.1002/ajh.26775.
    

    >> Share

    
    
18. MAIRA D, Duca L, Busti F, Consonni D, et al
    The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID-19: The IRONCOVID study.
    Am J Hematol. 2022;97:1404-1412.
    

    >> Share

    
    
19. MINNITI C, Brugnara C, Steinberg MH
    HbSC disease: A time for progress.
    Am J Hematol. 2022;97:1390-1393.
    

    >> Share

    
    
20. SISSOKO A, Fricot-Monsinjon A, Roussel C, Manceau S, et al
    Erythrocytic vacuoles that accumulate a fluorescent dye predict spleen size and function in sickle cell disease.
    Am J Hematol. 2022;97:E385-E388.
    

    >> Share

    
    
21. REES CA, Brousseau DC, Ahmad FA, Bennett J, et al
    Adherence to NHLBI guidelines for the emergent management of vaso-occlusive episodes in children with sickle cell disease: A multicenter perspective.
    Am J Hematol. 2022;97:E412-E415.
    

    >> Share

    
    
22. DAVID MS, Jones J, Lauriello A, Nnake I, et al
    Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization.
    Am J Hematol. 2022;97:1435-1442.
    

    >> Share

    
    October 2022
23. DI MODICA SM, Tanzi E, Olivari V, Lidonnici MR, et al
    Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent beta-thalassemia.
    Am J Hematol. 2022;97:1324-1336.
    

    >> Share

    
    
24. MKOMBACHEPA M, Khamis B, Rwegasira G, Urio F, et al
    High incidence of malaria in patients with sickle cell disease.
    Am J Hematol. 2022;97:E380-E381.
    

    >> Share

    
    
25. GIBSON SJ, Kalfa TA, DeStefano CB
    Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis.
    Am J Hematol. 2022;97:1384-1385.
    

    >> Share

    
    
26. LEWIS J, Greenway SC, Khan F, Singh G, et al
    Assessment of donor cell engraftment after hematopoietic stem cell transplantation for sickle cell disease: A review of current and future methods.
    Am J Hematol. 2022;97:1359-1371.
    

    >> Share

    
    September 2022
27. MORIS W, Koek GH, van Deursen CTBM
    A comment on: "Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial".
    Am J Hematol. 2022 Sep 23. doi: 10.1002/ajh.26740.
    

    >> Share

    
    
28. DHEDIN N, Chevillon F, Castelle M, Lavoipiere V, et al
    HLA-matched related donor hematopoietic stem cell transplantation is a suitable treatment in adolescents and adults with sickle cell disease: Comparison of myeloablative and non-myeloablative approaches.
    Am J Hematol. 2022;97:E359-E362.
    

    >> Share

    
    
29. PORTELA GT, Butters MA, Brooks MM, Candra L, et al
    Comprehensive assessment of cognitive function in adults with moderate and severe sickle cell disease.
    Am J Hematol. 2022;97:E344-E346.
    

    >> Share

    
    August 2022
30. BHUTANI G, Leung N, Said SM, Valeri AM, et al
    The Prevalence and Clinical Outcomes of Microangiopathic Hemolytic Anemia in Patients with Biopsy Proven Renal Thrombotic Microangiopathy.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26705.
    

    >> Share

    
    
31. NARDO-MARINO A, Glenthoj A, Brewin JN, Petersen J, et al
    The significance of spleen size in children with sickle cell anemia.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26703.
    

    >> Share

    
    
32. WAHEED A, Kuter DJ
    Hematological support of patients with significant anemia who decline red blood cell blood transfusion.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26701.
    

    >> Share

    
    
33. SZEPETOWSKI S, Berger C, Joly P, Baron-Joly S, et al
    Homozygosity for the hyperunstable hemoglobin variant Hb Agrinio (HBA2:c.89T>C) leads to severe antenatal anemia: Eight new cases in three families.
    Am J Hematol. 2022 Aug 12. doi: 10.1002/ajh.26687.
    

    >> Share

    
    
34. NAGALAPURAM V, Kanter J
    Multi-organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease.
    Am J Hematol. 2022;97:E318-E320.
    

    >> Share

    
    
35. GRAF M, Tuly R, Gallagher M, Sullivan J, et al
    Value of a cure for sickle cell disease in reducing economic disparities.
    Am J Hematol. 2022;97:E289-E291.
    

    >> Share

    
    
36. LE MONNIER O, Joseph L, Bodard S, Boudhabhay I, et al
    Hepato-splenic abscesses in a sickle cell disease patient.
    Am J Hematol. 2022;97:1118-1119.
    

    >> Share

    
    
37. LAI YR, Cappellini MD, Aydinok Y, Porter J, et al
    An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results.
    Am J Hematol. 2022;97:E281-E284.
    

    >> Share

    
    
38. MANSOUR-HENDILI L, Flamarion E, Michel M, Morbieu C, et al
    Acquired spherocytosis due to somatic ANK1 mutations as a manifestation of clonal hematopoiesis in elderly patients.
    Am J Hematol. 2022;97:E285-E288.
    

    >> Share

    
    
39. OSUNKWO I, James J, El-Rassi F, Nero A, et al
    Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high- and low- to middle-income countries for the international Sickle Cell World Assessment Survey.
    Am J Hematol. 2022;97:1055-1064.
    

    >> Share

    
    July 2022
40. POUCHELON C, Lafont C, Lafarge A, Comont T, et al
    Characteristics and Outcome of Adults With Severe Autoimmune Hemolytic Anemia Admitted to the Intensive Care Unit: Results From A Large French Observational Study.
    Am J Hematol. 2022 Jul 24. doi: 10.1002/ajh.26665.
    

    >> Share

    
    
41. KARKOSKA K, Pfeiffer A, Beebe DW, Quinn CT, et al
    Early hydroxyurea use is neuroprotective in children with sickle cell anemia.
    Am J Hematol. 2022 Jul 14. doi: 10.1002/ajh.26664.
    

    >> Share

    
    
42. MINETTI G, Bogdanova AY, Mairbaurl H, Kaestner L, et al
    Space anemia unexplained: Red blood cells seem to be space-proof.
    Am J Hematol. 2022 Jul 14. doi: 10.1002/ajh.26663.
    

    >> Share

    
    
43. KRALOVA B, Sochorcova L, Song J, Jahoda O, et al
    Developmental changes in iron metabolism and erythropoiesis in mice with human gain-of-function erythropoietin receptor.
    Am J Hematol. 2022 Jul 11. doi: 10.1002/ajh.26658.
    

    >> Share

    
    
44. XIAOHUA L, Liu Y, Qu C, Mol B, et al
    The association of iron deficiency anemia, thrombocytosis at delivery and postpartum venous thromboembolism.
    Am J Hematol. 2022 Jul 9. doi: 10.1002/ajh.26657.
    

    >> Share

    
    
45. BREWIN JN, Nardo-Marino A, Stuart-Smith S, El Hoss S, et al
    The pleiotropic effects of alpha thalassemia on HbSS and HbSC sickle cell disease: reduced erythrocyte cation co-transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival.
    Am J Hematol. 2022 Jul 8. doi: 10.1002/ajh.26652.
    

    >> Share

    
    
46. WESTIN ER, Tsao DS, Atay O, Landry BP, et al
    Validation of single-gene noninvasive prenatal testing for sickle cell disease.
    Am J Hematol. 2022;97:E270-E273.
    

    >> Share

    
    
47. DE LUNA G, Habibi A, Odievre MH, Guillet H, et al
    Blood exchange transfusion with dexamethasone and Tocilizumab for management of hospitalized patients with sickle cell disease and severe COVID-19: Preliminary evaluation of a novel algorithm.
    Am J Hematol. 2022;97:E260-E264.
    

    >> Share

    
    
48. VITTAL A, Alao H, Hercun J, Sharma B, et al
    Safety of liver biopsy in patients with sickle cell related liver disease: A single-center experience.
    Am J Hematol. 2022;97:E257-E260.
    

    >> Share

    
    
49. VAN DIJK MJ, Rab MAE, van Oirschot BA, Bos J, et al
    Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study.
    Am J Hematol. 2022;97:E226-E229.
    

    >> Share

    
    
50. WONG KH, Soffer GK
    Characteristics and prevalence of antibiotic allergies in patients with sickle cell disease: A single-center retrospective study.
    Am J Hematol. 2022;97:E247-E249.
    

    >> Share

    
    
51. GIANNOTTA JA, Fattizzo B, Bortolotti M, Girmenia C, et al
    SARS-CoV-2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey.
    Am J Hematol. 2022;97:E229-E232.
    

    >> Share

    
    June 2022
52. KOURY MJ, Agarwal R, Chertow GM, Eckardt KU, et al
    Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.
    Am J Hematol. 2022 Jun 25. doi: 10.1002/ajh.26644.
    

    >> Share

    
    
53. BAIN BJ, Myburgh J, Hann A, Layton DM, et al
    Voxelotor in sickle cell disease.
    Am J Hematol. 2022;97:830-832.
    

    >> Share

    
    
54. YOUNG DJ, Fan X, Groarke EM, Patel B, et al
    Long-term eltrombopag for bone marrow failure depletes iron.
    Am J Hematol. 2022;97:791-801.
    

    >> Share

    
    May 2022
55. KRONER BL, Hankins JS, Pugh N, Kutlar A, et al
    Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.
    Am J Hematol. 2022;97:603-612.
    

    >> Share

    
    April 2022
56. VAN VUREN A, Kerkhoffs JL, Schols S, Rijneveld A, et al
    Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo-controlled randomized cross-over clinical trial. NIH.
    Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26581.
    

    >> Share

    
    
57. NAAMI N, Borkhardt A, Yoshimi A, Grinstein L, et al
    13-month-old girl with hyporegenerative macrocytic anemia due to Brown-Vialetto-Van Laere syndrome 2.
    Am J Hematol. 2022 Apr 20. doi: 10.1002/ajh.26573.
    

    >> Share

    
    
58. PLESSIER A, Esposito-Farese M, Baiges A, Shukla A, et al
    Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications.
    Am J Hematol. 2022;97:431-439.
    

    >> Share

    
    
59. AYGUN B, Bello A, Thompson AA, Davis L, et al
    Clinical phenotypes of three children with sickle cell disease caused by HbS/Sicilian (deltabeta)(0) -thalassemia deletion.
    Am J Hematol. 2022;97:E156-E158.
    

    >> Share

    
    
60. SIVAGURU G, Simini G, Bain BJ
    Persistent neonatal jaundice resulting from hereditary pyropoikilocytosis.
    Am J Hematol. 2022;97:506-507.
    

    >> Share

    
    March 2022
61. ARLET JB, Lionnet F, Khimoud D, Joseph L, et al
    Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France.
    Am J Hematol. 2022;97:E86-E91.
    

    >> Share

    
    
62. SCHWARTZ JD, Barcellini W, Grace RF, Bianchi P, et al
    Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD.
    Am J Hematol. 2022;97:E120-E125.
    

    >> Share

    
    
63. CURTIS SA, Betancourt J, Kottapalli N, Campbell S, et al
    Voxelotor use in adults with sickle cell disease in a real-world setting.
    Am J Hematol. 2022;97:E125-E128.
    

    >> Share

    
    
64. BRADFORD C, Miodownik H, Thomas M, Ogu UO, et al
    Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease.
    Am J Hematol. 2022;97:E93-E95.
    

    >> Share

    
    
65. ALLALI S, Chhun S, de Montalembert M, Heilbronner C, et al
    Tocilizumab for severe acute chest syndrome in a child with sickle cell disease and dramatically high interleukin-6 values in endotracheal and pleural fluids.
    Am J Hematol. 2022;97:E81-E83.
    

    >> Share

    
    February 2022
66. KUTER DJ, Rogers KA, Boxer MA, Choi M, et al
    Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26508.
    

    >> Share

    
    
67. OLUPOT-OLUPOT P, Connon R, Kiguli S, Opoka RO, et al
    A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa.
    Am J Hematol. 2022 Feb 11. doi: 10.1002/ajh.26492.
    

    >> Share

    
    
68. FIELDS ME, Mirro AE, Binkley MM, Guilliams KP, et al
    Cerebral Oxygen Metabolic Stress is Increased in Children with Sickle Cell Anemia Compared to Anemic Controls.
    Am J Hematol. 2022 Feb 3. doi: 10.1002/ajh.26485.
    

    >> Share

    
    
69. ANGELI AM, Megna B, Mazepa M, Ivy ZK, et al
    Transfusion-Dependent Anemia Secondary to Vitamin C Deficiency.
    Am J Hematol. 2022 Feb 2. doi: 10.1002/ajh.26484.
    

    >> Share

    
    
70. LONGO F, Gianesin B, Voi V, Motta I, et al
    Italian patients with hemoglobinopathies exhibit a 5-fold increase in age-standardized lethality due to SARS-CoV-2 infection.
    Am J Hematol. 2022;97:E75-E78.
    

    >> Share

    
    
71. PATNAIK MM, Santini V
    Targeting ineffective hematopoiesis in myelodysplastic syndromes.
    Am J Hematol. 2022;97:171-173.
    

    >> Share

    
    
72. ANDOLFO I, Alper SL, Iolascon A
    Nobel prize in physiology or medicine 2021, receptors for temperature and touch: Implications for hematology.
    Am J Hematol. 2022;97:168-170.
    

    >> Share

    
    
73. TVEDT THA, Steien E, Ovrebo B, Haaverstad R, et al
    Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery.
    Am J Hematol. 2022;97:E51-E54.
    

    >> Share

    
    January 2022
74. CHIN-YEE B, Cheong I, Matyashin M, Lazo-Langner A, et al
    Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysis.
    Am J Hematol. 2022 Jan 19. doi: 10.1002/ajh.26471.
    

    >> Share

    
    
75. DORES GM, Nayernama A, Cheng C, Moureaud C, et al
    Hemolytic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Event Reporting System.
    Am J Hematol. 2022 Jan 5. doi: 10.1002/ajh.26454.
    

    >> Share

    
    
76. FEJTKOVA M, Sukova M, Hlozkova K, Skvarova Kramarzova K, et al
    TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins.
    Am J Hematol. 2022 Jan 3. doi: 10.1002/ajh.26452.
    

    >> Share

    
    
77. RIBEIL JA
    Primary myelofibrosis in untreated sickle cell disease: Are adult patients at higher risk for developing hematological myeloid neoplasms?
    Am J Hematol. 2022;97:4-6.
    

    >> Share

    
    
78. REYES LZ, Figueroa J, Leake D, Khemani K, et al
    Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso-occlusive pain: A randomized placebo-controlled trial in progress.
    Am J Hematol. 2022;97:E21-E24.
    

    >> Share

    
    
79. FORD AL, Hsu HC, Binkley MM, Rogers S, et al
    Probing single-cell oxygen reserve in sickled erythrocytes via in vivo photoacoustic microscopy.
    Am J Hematol. 2022;97:E11-E14.
    

    >> Share

    
    
80. GREEN SE, Singh ZN, Baer MR
    Primary myelofibrosis in a patient with sickle cell disease.
    Am J Hematol. 2022;97:160-161.
    

    >> Share

    
    December 2021
81. RUIZ MA, Shah BN, Ren G, Shuey D, et al
    Thrombomodulin and Multi-Organ Failure in Sickle Cell Anemia.
    Am J Hematol. 2021 Dec 20. doi: 10.1002/ajh.26443.
    

    >> Share

    
    
82. MUSALLAM KM, Vitrano A, Meloni A, Addario Pollina S, et al
    Risk of mortality from anemia and iron overload in non-transfusion-dependent beta-thalassemia.
    Am J Hematol. 2021 Dec 4. doi: 10.1002/ajh.26428.
    

    >> Share

    
    
83. JOHNSON S, Gordeuk VR, Machado R, Gibbs JSR, et al
    Exercise-induced changes of vital signs in adults with sickle cell disease.
    Am J Hematol. 2021;96:1630-1638.
    

    >> Share

    
    November 2021
84. GERBER GF, DeZern AE, Chaturvedi S, Brodsky RA, et al
    A 15-year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism.
    Am J Hematol. 2021 Nov 20. doi: 10.1002/ajh.26414.
    

    >> Share

    
    
85. FATTIZZO B, Giannotta JA, Cecchi N, Barcellini W, et al
    SARS-CoV-2 vaccination in patients with autoimmune cytopenias: The experience of a reference center.
    Am J Hematol. 2021;96:E413-E416.
    

    >> Share

    
    
86. HENRY DH, Glaspy J, Harrup R, Mittelman M, et al
    Roxadustat for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome: Open-label, Dose-selection, Lead-in Stage of a Phase 3 Study.
    Am J Hematol. 2021 Nov 1. doi: 10.1002/ajh.26397.
    

    >> Share

    
    
87. KOUNTOURIS P, Stephanou C, Archer N, Bonifazi F, et al
    The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies.
    Am J Hematol. 2021;96:E416-E420.
    

    >> Share

    
    
88. MARTIN ES, Ferrer A, Mangaonkar AA, Khan SP, et al
    Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
    Am J Hematol. 2021;96:1450-1460.
    

    >> Share

    
    
89. LONGORIA JN, Pugh NL, Gordeuk V, Hsu LL, et al
    Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease.
    Am J Hematol. 2021;96:1396-1406.
    

    >> Share

    
    
90. MUSALLAM KM, Bou-Fakhredin R, Cappellini MD, Taher AT, et al
    2021 update on clinical trials in beta-thalassemia.
    Am J Hematol. 2021;96:1518-1531.
    

    >> Share

    
    
91. HEBBEL RP, Vercellotti GM
    Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease.
    Am J Hematol. 2021;96:1505-1517.
    

    >> Share

    
    October 2021
92. MAKHARADZE T, Boccia R, Krupa A, Blackman N, et al
    Efficacy and Safety of Ferric Carboxymaltose Infusion in Reducing Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: a Randomized, Placebo-Controlled Study (IRON CLAD).
    Am J Hematol. 2021 Oct 15. doi: 10.1002/ajh.26376.
    

    >> Share

    
    
93. COX HD, Miller GD, Manandhar A, Husk JD, et al
    Tracking immature reticulocyte proteins for improved detection of recombinant human erythropoietin (rhEPO) abuse.
    Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26368.
    

    >> Share

    
    
94. ASPERTI M, Brilli E, Denardo A, Gryzik M, et al
    Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.
    Am J Hematol. 2021;96:1253-1263.
    

    >> Share

    
    
95. DE MONTALEMBERT M, Voskaridou E, Oevermann L, Cannas G, et al
    Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
    Am J Hematol. 2021;96:1223-1231.
    

    >> Share

    
    
96. PIATTI G, Giuditta M, Pierini A, Consonni D, et al
    Muscular de-conditioning and reduced cardiac inotropism due to iron deposition reduce exercise tolerance in beta thalassemia major.
    Am J Hematol. 2021;96:E370-E373.
    

    >> Share

    
    September 2021
97. VIRK ZM, Patel AA, Leaf RK, Al-Samkari H, et al
    Predictors of Mortality and Outcomes of Liver Transplant in Spur Cell Hemolytic Anemia.
    Am J Hematol. 2021 Sep 22. doi: 10.1002/ajh.26359.
    

    >> Share

    
    
98. PETIT AF, Kulasekararaj AG, Eikema DJ, Maschan A, et al
    Upfront unrelated donor Hematopoietic stem cell transplantation in patients with idiopathic aplastic anemia: a retrospective study of the Severe Aplastic Anemia Working Party of European Bone Marrow Transplantation.
    Am J Hematol. 2021 Sep 22. doi: 10.1002/ajh.26354.
    

    >> Share

    
    
99. MEZNARICH JA, Rets A, Agarwal AM, Christensen RD, et al
    Novel, De Novo, Beta-Globin Variant with Decreased Oxygen Affinity (HBB:C.317T>A, "Hemoglobin St. George") in a Healthy Child with Low Oxygen Saturations and Anemia.
    Am J Hematol. 2021 Sep 22. doi: 10.1002/ajh.26356.
    

    >> Share

    
    
100. YE L, Jing L, Guo J, Zhao X, et al
     Red Blood Cell Lifespan is Reduced in Severe Aplastic Anemia and Improves with Response to Immunosuppressive Treatment.
     Am J Hematol. 2021 Sep 2. doi: 10.1002/ajh.26344.
     

     >> Share

     
     
101. D'HUMIERES T, Savale L, Inamo J, Deux JF, et al
     Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis.
     Am J Hematol. 2021;96:1166-1175.
     

     >> Share

     
     
102. ROGER C, Lionnet F, Mattioni S, Livrozet M, et al
     Risk factors for CKD stage II onset in a prospective cohort of homozygous sickle cell adults.
     Am J Hematol. 2021;96:1147-1155.
     

     >> Share

     
     
103. MANSOUR-HENDILI L, Egee S, Monedero-Alonso D, Bouyer G, et al
     Multiple thrombosis in a patient with Gardos channelopathy and a new KCNN4 mutation.
     Am J Hematol. 2021;96:E318-E321.
     

     >> Share

     
     
104. VAN VUREN AJ, Minniti CP, Mendelsohn L, Baird JH, et al
     Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in sickle cell disease.
     Am J Hematol. 2021;96:E315-E318.
     

     >> Share

     
     August 2021
105. PEREZ BOTERO J, Reese JA, George JN, McIntosh JJ, et al
     Severe Thrombocytopenia and Microangiopathic Hemolytic Anemia in Pregnancy: A Guide for the Consulting Hematologist.
     Am J Hematol. 2021 Aug 23. doi: 10.1002/ajh.26328.
     

     >> Share

     
     
106. DEXTER D, Layton DM, Kiritkumar K, Bain BJ, et al
     Peripheral blood features of iron overload in post-splenectomy, type I congenital dyserythropoietic anemia.
     Am J Hematol. 2021 Aug 20. doi: 10.1002/ajh.26327.
     

     >> Share

     
     
107. SHIMANO KA, Narla A, Rose MJ, Gloude NJ, et al
     Diagnostic work-up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium.
     Am J Hematol. 2021 Aug 3. doi: 10.1002/ajh.26310.
     

     >> Share

     
     
108. PEREZ-LAMAS L, Moreno-Jimenez G, Tenorio-Nunez MC, Velazquez-Kennedy K, et al
     Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease.
     Am J Hematol. 2021;96:E288-E291.
     

     >> Share

     
     
109. BOU-FAKHREDIN R, Daadaa H, Koussa S, Abou Nasr T, et al
     SARS-CoV-2 infection in patients with beta-thalassemia: Experience from Lebanon.
     Am J Hematol. 2021;96:E285-E288.
     

     >> Share

     
     
110. HAYFRON-BENJAMIN CF, Asare EV, Boafor T, Olayemi E, et al
     Low FEV1 is associated with fetal death in pregnant women with sickle cell disease.
     Am J Hematol. 2021;96:E303-E306.
     

     >> Share

     
     
111. EDJLALI M, Gobin-Metteil MP, Mele N, Maier B, et al
     Transcranial color-coded duplex sonography reliably identifies intracranial vasculopathy in adult patients with sickle cell disease.
     Am J Hematol. 2021;96:961-967.
     

     >> Share

     
     
112. VU C, Bush A, Choi S, Borzage M, et al
     Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias.
     Am J Hematol. 2021;96:901-913.
     

     >> Share

     
     
113. KNEE KM, Jasuja R, Barakat A, Rao D, et al
     PF-07059013: A non-covalent hemoglobin modulator favorably impacts disease state in a mouse model of sickle cell disease.
     Am J Hematol. 2021;96:E272-E275.
     

     >> Share

     
     
114. MALECKA A, Troen G, Delabie J, Malecki J, et al
     The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels.
     Am J Hematol. 2021;96:E279-E283.
     

     >> Share

     
     
115. JANKOVSKY N, Caulier A, Demagny J, Guitton C, et al
     Recent advances in the pathophysiology of PIEZO1-related hereditary xerocytosis.
     Am J Hematol. 2021;96:1017-1026.
     

     >> Share

     
     
116. FAN BE, Cao L, Gallardo CA, Lee SMS, et al
     Myeloid and lymphoid vacuolation in VEXAS syndrome.
     Am J Hematol. 2021;96:1056-1057.
     

     >> Share

     
     July 2021
117. HANSEN DL, Berentsen S, Fattizzo B, Hansen PL, et al
     Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy.
     Am J Hematol. 2021;96:E262-E265.
     

     >> Share

     
     
118. WAHEED A, Kuter DJ
     Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria.
     Am J Hematol. 2021;96:E235-E237.
     

     >> Share

     
     
119. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Darbaniyan F, Siddiqui MT, et al
     Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
     Am J Hematol. 2021;96:E246-E249.
     

     >> Share

     
     
120. KULASEKARARAJ AG, Brodsky RA, Hill A
     Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor.
     Am J Hematol. 2021;96:E232-E235.
     

     >> Share

     
     June 2021
121. GURUNG K, Bain BJ
     A normal mean cell volume does not exclude a diagnosis of megaloblastic anemia.
     Am J Hematol. 2021 Jun 24. doi: 10.1002/ajh.26283.
     

     >> Share

     
     
122. KIRK SE, Scheurer ME, Bernhardt MB, Mahoney DH, et al
     Phosphorus levels in children treated with intravenous ferric carboxymaltose.
     Am J Hematol. 2021;96:E215-E218.
     

     >> Share

     
     
123. PANAGIOTA V, Meggendorfer M, Kubasch AS, Gabdoulline R, et al
     Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
     Am J Hematol. 2021;96:E207-E210.
     

     >> Share

     
     
124. ZHANG X, Yang Y, Zhang H, Du Z, et al
     A rare complex rearrangement in the beta-globin gene cluster causing a novel homozygous (G) gamma((A) gammadeltabeta)(0) -thalassemia.
     Am J Hematol. 2021;96:E189-E193.
     

     >> Share

     
     May 2021
125. RAMIREZ MJ, Pujol R, Trujillo-Quintero JP, Minguillon J, et al
     Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients.
     Am J Hematol. 2021 May 13. doi: 10.1002/ajh.26234.
     

     >> Share

     
     
126. KIM SJ, Song J, Reading NS, Lautersztain J, et al
     Novel mechanism of hereditary pyropoikilocytosis phenotype due to co-inheritance of beta globin and alpha spectrin mutations.
     Am J Hematol. 2021;96:E150-E154.
     

     >> Share

     
     
127. KALANTAR-ZADEH K, Ganz T, Trumbo H, Seid MH, et al
     Parenteral iron therapy and phosphorus homeostasis: A review.
     Am J Hematol. 2021;96:606-616.
     

     >> Share

     
     
128. BAIN BJ
     Alpha chain inclusions in peripheral blood erythroblasts and erythrocytes.
     Am J Hematol. 2021;96:630-631.
     

     >> Share

     
     April 2021
129. MAQUET J, Lafaurie M, Walter O, Sailler L, et al
     Epidemiology of autoimmune hemolytic anemia: a nationwide population-based study in France.
     Am J Hematol. 2021 Apr 30. doi: 10.1002/ajh.26213.
     

     >> Share

     
     
130. BARCELLINI W, Zaninoni A, Giannotta JA, Merati G, et al
     Circulating extracellular vesicles and cytokines in congenital and acquired hemolytic anemias.
     Am J Hematol. 2021;96:E129-E132.
     

     >> Share

     
     
131. MINNITI CP, Knight-Madden J, Tonda M, Gray S, et al
     The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease.
     Am J Hematol. 2021;96:E126-E128.
     

     >> Share

     
     
132. AL-ALI AK, Alsulaiman A, Alfarhan M, Safaya S, et al
     Sickle cell disease in the Eastern Province of Saudi Arabia: Clinical and laboratory features.
     Am J Hematol. 2021;96:E117-E121.
     

     >> Share

     
     
133. MCGRATH M, Quint EH, Weyand AC
     Depression in adolescents and young adults with heavy menstrual bleeding in a referral clinic setting.
     Am J Hematol. 2021;96:E105-E108.
     

     >> Share

     
     
134. ARCHULETA J, van der Graaf M, Kaptein FHJ, Althaus L, et al
     Sudden death due to massive bone marrow sequestration crisis in a patient with sickle cell disease.
     Am J Hematol. 2021;96:E100-E102.
     

     >> Share

     
     
135. OSUNKWO I, Andemariam B, Minniti CP, Inusa BPD, et al
     Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY).
     Am J Hematol. 2021;96:404-417.
     

     >> Share

     
     
136. LANZKRON S, Smith-Whitley K
     Swaying sickle cell research forward in support of patient reported outcomes.
     Am J Hematol. 2021;96:402-403.
     

     >> Share

     
     March 2021
137. PATNAIK MM, Tefferi A
     Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
     Am J Hematol. 2021;96:379-394.
     

     >> Share

     
     
138. DENTON CC, Shah P, Suriany S, Liu H, et al
     Loss of alpha-globin genes in human subjects is associated with improved nitric oxide-mediated vascular perfusion.
     Am J Hematol. 2021;96:277-281.
     

     >> Share

     
     
139. MUSALLAM KM, Rivella S, Taher AT
     Management of non-transfusion-dependent beta-thalassemia (NTDT): The next 5 years.
     Am J Hematol. 2021;96:E57-E59.
     

     >> Share

     
     February 2021
140. ZUBICARAY J, Pagliara D, Sevilla J, Eikema DJ, et al
     Haplo-identical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: results from the Severe Aplastic Anemia Working Party of the EBMT.
     Am J Hematol. 2021 Feb 19. doi: 10.1002/ajh.26135.
     

     >> Share

     
     
141. ROMANA M, Reminy K, Moeckesch B, Charlot K, et al
     Loss of alpha globin genes is associated with improved microvascular function in patients with sickle cell anemia.
     Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26126.
     

     >> Share

     
     
142. AUERBACH M, Henry D, DeLoughery TG
     Intravenous ferric derisomaltose for the treatment of iron deficiency anemia.
     Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26124.
     

     >> Share

     
     
143. KARKOSKA K, Quinn CT, Niss O, Pfeiffer A, et al
     Hydroyxurea improves cerebral oxygen saturation in children with sickle cell anemia.
     Am J Hematol. 2021 Feb 3. doi: 10.1002/ajh.26120.
     

     >> Share

     
     
144. LEBENSBURGER JD, Aban I, Hilliard LM, Feig DI, et al
     Hyperuricemia and Abnormal Nocturnal Dipping Impact Glomerular Filtration Rate in Patients with Sickle Cell Anemia.
     Am J Hematol. 2021 Feb 1. doi: 10.1002/ajh.26115.
     

     >> Share

     
     
145. MUSALLAM KM, Cappellini MD, Viprakasit V, Kattamis A, et al
     Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later.
     Am J Hematol. 2021;96:E54-E56.
     

     >> Share

     
     
146. SCHMIDT PJ, Fitzgerald K, Butler JS, Fleming MD, et al
     Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
     Am J Hematol. 2021;96:251-257.
     

     >> Share

     
     January 2021
147. LUNATI A, Petit A, Lapillonne H, Gameiro C, et al
     VPS4A mutation in syndromic congenital hemolytic anemia without obvious signs of dyserythropoiesis.
     Am J Hematol. 2021 Jan 18. doi: 10.1002/ajh.26099.
     

     >> Share

     
     
148. GLADWIN MT, Kato GJ, Gordeuk VR
     Identifying adolescent and young adult patients with sickle cell disease at highest risk of death.
     Am J Hematol. 2021;96:9-11.
     

     >> Share

     
     
149. RAB MAE, Kanne CK, Bos J, van Oirschot BA, et al
     Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease.
     Am J Hematol. 2021;96:E29-E32.
     

     >> Share

     
     
150. ROSANWO TO, Kean LS, Archer NM
     End the pain: Start with antiracism.
     Am J Hematol. 2021;96:4-6.
     

     >> Share

     
     
151. OGU UO, Thomas M, Chan F, Vattappally L, et al
     L-glutamine use in adults with sickle cell disease: Clinical trials where success meets reality.
     Am J Hematol. 2021;96:E38-E40.
     

     >> Share

     
     
152. CHALACHEVA P, Ji Y, Rosen CL, DeBaun MR, et al
     Nocturnal peripheral vasoconstriction predicts the frequency of severe acute pain episodes in children with sickle cell disease.
     Am J Hematol. 2021;96:60-68.
     

     >> Share

     
     
153. COSTA E, Tibalinda P, Sterzi E, Leufkens HMG, et al
     Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost.
     Am J Hematol. 2021;96:E2-E5.
     

     >> Share

     
     
154. SHAH P, Suriany S, Kato R, Bush AM, et al
     Tricuspid regurgitant jet velocity and myocardial tissue Doppler parameters predict mortality in a cohort of patients with sickle cell disease spanning from pediatric to adult age groups - revisiting this controversial concept after 16 years of additi
     Am J Hematol. 2021;96:31-39.
     

     >> Share

     
     December 2020
155. KARKOSKA K, Quinn CT, Clapp K, McGann PT, et al
     Severe infusion-related reaction to crizanlizumab in an adolescent with sickle cell disease.
     Am J Hematol. 2020;95:E338-E339.
     

     >> Share

     
     
156. COHEN J, Khudanyan A, Lu J, Wing J, et al
     A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency.
     Am J Hematol. 2020;95:1572-1577.
     

     >> Share

     
     November 2020
157. DAVIS BH
     Assay for "fetal hemoglobin levels" in erythrocytes: Impact of new In Vitro Diagnostics regulation and expanded applications in sickle cell disease management.
     Am J Hematol. 2020;95:1230-1232.
     

     >> Share

     
     
158. ANGELUCCI E
     Can any new thalassemia therapy achieve a better than 97.4% cure rate?
     Am J Hematol. 2020;95:1233-1234.
     

     >> Share

     
     
159. HE Y, Jiang H, Li C, Zhu Y, et al
     Long-term results of the NF-08-TM protocol in stem cell transplant for patients with thalassemia major: A multi-center large-sample study.
     Am J Hematol. 2020;95:E297-E299.
     

     >> Share

     
     
160. RUSSO R, Marra R, Andolfo I, Manna F, et al
     Uridine treatment normalizes the congenital dyserythropoietic anemia type II-like hematological phenotype in a patient with homozygous mutation in the CAD gene.
     Am J Hematol. 2020;95:1423-1426.
     

     >> Share

     
     
161. MERLET AN, Feasson L, Bartolucci P, Hourde C, et al
     Muscle structural, energetic and functional benefits of endurance exercise training in sickle cell disease.
     Am J Hematol. 2020;95:1257-1268.
     

     >> Share

     
     
162. HEBERT N, Rakotoson MG, Bodivit G, Audureau E, et al
     Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease.
     Am J Hematol. 2020;95:1235-1245.
     

     >> Share

     
     
163. KUCUKAL E, Man Y, Hill A, Liu S, et al
     Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease.
     Am J Hematol. 2020;95:1246-1256.
     

     >> Share

     
     
164. DE CASTRO C, Grossi F, Weitz IC, Maciejewski J, et al
     C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
     Am J Hematol. 2020;95:1334-1343.
     

     >> Share

     
     October 2020
165. POLLYEA DA, Pratz K, Letai A, Jonas BA, et al
     Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study.
     Am J Hematol. 2020 Oct 29. doi: 10.1002/ajh.26039.
     

     >> Share

     
     
166. ONALO R, Cooper P, Cilliers A, Vorster BC, et al
     Randomized Control Trial of Oral Arginine Therapy for Children with Sickle Cell Anemia Hospitalized for Pain in Nigeria.
     Am J Hematol. 2020 Oct 19. doi: 10.1002/ajh.26028.
     

     >> Share

     
     
167. WOLF M, Auerbach M, Kalra PA, Glaspy J, et al
     Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials.
     Am J Hematol. 2020 Oct 7. doi: 10.1002/ajh.26015.
     

     >> Share

     
     September 2020
168. DEBEER T, Jordan LC, Lee CA, Patel NJ, et al
     Evidence of transfusion-induced reductions in cerebral capillary shunting in sickle cell disease.
     Am J Hematol. 2020;95:E228-E230.
     

     >> Share

     
     
169. SONI S
     Gene therapies for transfusion dependent beta-thalassemia: Current status and critical criteria for success.
     Am J Hematol. 2020;95:1099-1112.
     

     >> Share

     
     
170. GALADANCI NA, Abdullahi SU, Ali Abubakar S, Wudil Jibir B, et al
     Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.
     Am J Hematol. 2020;95:E247-E250.
     

     >> Share

     
     
171. GEORGE A, Dinu B, Estrada N, Minard CG, et al
     Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease.
     Am J Hematol. 2020;95:E242-E244.
     

     >> Share

     
     
172. KNISELY MR, Pugh N, Kroner B, Masese R, et al
     Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium.
     Am J Hematol. 2020;95:1066-1074.
     

     >> Share

     
     
173. TISDALE JF, Pierciey FJ Jr, Bonner M, Thompson AA, et al
     Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial.
     Am J Hematol. 2020;95:E239-E242.
     

     >> Share

     
     
174. SCARAMELLINI N, Consonni D, Cassinerio E, Arighi C, et al
     A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 mug/L.
     Am J Hematol. 2020;95:E230-E232.
     

     >> Share

     
     
175. SIDANA S, Murray DL, Dasari S, Go RS, et al
     Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease.
     Am J Hematol. 2020;95:E222-E225.
     

     >> Share

     
     
176. TSEU B, Siow W, Pushkaran B, Cheesebrough B, et al
     Beta thalassemia major and Noonan syndrome - Two genetic disorders manifest in the blood film.
     Am J Hematol. 2020;95:1113-1114.
     

     >> Share

     
     April 2020
177. AL-BUBSEREE B, Leach M, Jones R, Bain BJ, et al
     The hematological effects of copper deficiency.
     Am J Hematol. 2020;95:446.
     

     >> Share

     
     
178. ESPINOZA J, Shah P, Veluswamy S, Zeltzer L, et al
     Aura and mental stress are associated with reports of pain in sickle cell disease-a pilot study using a mobile application.
     Am J Hematol. 2020;95:E101-E103.
     

     >> Share

     
     
179. DUTTA D, Li K, Methe B, Lim SH, et al
     Rifaximin on intestinally-related pathologic changes in sickle cell disease.
     Am J Hematol. 2020;95:E83-E86.
     

     >> Share

     
     
180. VACLAVU L, Petr J, Petersen ET, Mutsaerts HJMM, et al
     Cerebral oxygen metabolism in adults with sickle cell disease.
     Am J Hematol. 2020;95:401-412.
     

     >> Share

     
     
181. GONDELAUD F, Connes P, Nader E, Renoux C, et al
     Sialic acids rather than glycosaminoglycans affect normal and sickle red blood cell rheology by binding to four major sites on fibrinogen.
     Am J Hematol. 2020;95:E77-E80.
     

     >> Share

     
     January 2020
182. WALSH K, Blalock DV, Mehler PS
     Hematologic Findings in a Large Sample of Patients with Anorexia Nervosa and Bulimia Nervosa.
     Am J Hematol. 2020 Jan 15. doi: 10.1002/ajh.25732.
     

     >> Share

     
     
183. QASRAWI A, Arora R, Ramlal R, Munker R, et al
     Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
     Am J Hematol. 2020 Jan 9. doi: 10.1002/ajh.25725.
     

     >> Share

     
     

Free Medical Abstracts
Privacy Policy
Sponsors
Share